About OnCusp

OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.

We deliver

help and hope to

cancer patients worldwide.

Culture and Values

The OnCusp Therapeutics team has deep experience in the science and business of global medical innovation. We have shaped our company culture to draw on this knowledge, combining crisp, goal-oriented strategy with an emphasis on societal benefit and win-win partnerships. Our team works quickly but holds each other accountable so that quality is never compromised. We take smart risks and bet big when the situation calls for it. We value honesty. We structure our partnerships to share risk and reward in a fair, transparent manner while working to maximize value using our deep experience and global networks. We always keep an eye on results, not only in terms of value creation but, importantly, on our vision of the societal bottom line—the improved patient outcomes our work enables.

Company Milestones

  • Dec 2023

    Completed an oversubscribed Series A financing for $100 million

  • Aug 2023

    Received FDA clearance for the Phase I clinical trial of CUSP06

  • Apr 2023

    Showcased potent Anti-Tumor activity of its CDH6 ADC at AACR Annual Meeting 2023

  • Aug 2022

    Raised $14M in Series Seed Plus financing

  • Apr 2022

    Established global partnership (excluding China) with a Chinese biotech, to develop CUSP06

  • Oct 2021

    Established global partnership (excluding China) with a Chinese biotech to discover and develop CUSP03

  • Sept 2021

    Initiation of first In-House Program CUSP02

  • Jun 2021

    Opened New York office

  • Apr 2021

    Opened Shanghai office

  • Apr 2021

    - Company Founded
    - Completed $25 million seed round financing and started operations

Management Team

Scientific Advisory Board